Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 34 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNCompletedNCT03529422Phase 2Results posted
• Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain MetastasisCompletedNCT03526900Phase 2Results posted
• Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLCCompletedNCT03526887Phase 2Results posted
• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• Phase I/Ib Multiple Ascending Dose Study in ChinaCompletedNCT03523390Phase 1Results posted
• Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTerminatedNCT03522584Phase 1/2Results posted
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based ChemotherapyActive, not recruitingNCT03522246Phase 3Results posted
• Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell CancerCompletedNCT03521570Phase 2Results posted
• A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular CarcinomaCompletedNCT03519997Phase 2Results posted
• Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerCompletedNCT03519971Phase 3Results posted
• A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerTerminatedNCT03519308Early Phase 1Results posted
• A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the BladderTerminatedNCT03519256Phase 2Results posted
• Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])CompletedNCT03517449Phase 3Results posted
• Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)CompletedNCT03515837Phase 3Results posted
• REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung CancerTerminatedNCT03515629Phase 3Results posted
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted
• Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated MesotheliomaTerminatedNCT03502746Phase 2Results posted
• A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer PatientsTerminatedNCT03502681Phase 1Results posted
• A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast CancerCompletedNCT03499899Phase 2Results posted
• A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast CancerTerminatedNCT03498716Phase 3Results posted
• Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesTerminatedNCT03498612Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder CancerTerminatedNCT03498196Phase 1/2Results posted
• A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedNCT03495882Phase 1/2Results posted
• Lymphoma RadVax LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERSTerminatedNCT03495713Phase 2Results posted
• Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeCompletedNCT03493932Phase 1Results posted
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 2Results posted
• Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the PancreasTerminatedNCT03490760Phase 2Results posted
• Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedNCT03489369Phase 1Results posted
• Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedNCT03489343Phase 1Results posted
• OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual DiseaseCompletedNCT03487666Phase 2Results posted
• Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial CarcinomaTerminatedNCT03486197Phase 2Results posted
• Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell LymphomaCompletedNCT03484819Phase 2Results posted
• Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain MetastasisCompletedNCT03483012Phase 2Results posted
• Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal CancerCompletedNCT03475004Phase 2Results posted
• UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeActive, not recruitingNCT03474497Phase 1/2Results posted
• Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)CompletedNCT03473925Phase 2Results posted
• Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial CarcinomaCompletedNCT03473756Phase 1Results posted
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverCompletedNCT03472586Phase 2Results posted
• A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)TerminatedNCT03472560Phase 2Results posted
• A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerCompletedNCT03472365Phase 2Results posted
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced MelanomaActive, not recruitingNCT03470922Phase 2/3Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results posted
• Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular LymphomaTerminatedNCT03465891Phase 2Results posted
• A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
• Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior ImmunotherapyTerminatedNCT03463161Phase 2Results posted
• Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)TerminatedNCT03461952Phase 2Results posted
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results posted
• A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)CompletedNCT03456063Phase 3Results posted
• Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung CancerTerminatedNCT03455556Phase 1Results posted
• Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)CompletedNCT03453164Phase 1/2Results posted
• Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsTerminatedNCT03451825Phase 1Results posted
• An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have SpreadTerminatedNCT03446040Phase 1/2Results posted
• A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaTerminatedNCT03445533Phase 3Results posted
• Study of Nivolumab for Advanced Cancers in IndiaCompletedNCT03444766Phase 4Results posted
• PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCCompletedNCT03442569Phase 2Results posted
• Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver CancerCompletedNCT03439891Phase 2Results posted
• DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated CancersTerminatedNCT03439085Phase 2Results posted
• Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression RiskCompletedNCT03436862Phase 2Results posted
• Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal CancerCompletedNCT03435107Phase 2Results posted
• A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular CarcinomaCompletedNCT03434379Phase 3Results posted
• This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of CancerCompletedNCT03433898Early Phase 1Results posted
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Phase 3Results posted
• Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaTerminatedNCT03430791Phase 2Results posted
• Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerCompletedNCT03430700Phase 2Results posted
• A Study of REGN2810 and Ipilimumab in Patients With Lung CancerTerminatedNCT03430063Phase 2Results posted
• Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic InstabilityActive, not recruitingNCT03428802Phase 2Results posted
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerCompletedNCT03428126Phase 2Results posted
• Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed GlioblastomaCompletedNCT03426891Phase 1Results posted
• Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)Active, not recruitingNCT03425643Phase 3Results posted
• A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell CancerCompletedNCT03425565Phase 2Results posted
• Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCTerminatedNCT03425331Phase 2Results posted
• Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung CancerTerminatedNCT03425006Phase 2Results posted
• Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for ChemoCompletedNCT03421652Phase 2Results posted
• Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results posted
• Study of BGB-A317 in Participants With Previously Treated Unresectable HCCCompletedNCT03419897Phase 2Results posted
• A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular CarcinomaCompletedNCT03418922Phase 1Results posted
• SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyCompletedNCT03417895Phase 2Results posted
• Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BCCompletedNCT03417544Phase 2Results posted
• A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic ProfileTerminatedNCT03416335Phase 1/2Results posted
• An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has SpreadCompletedNCT03414983Phase 2/3Results posted
• Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast CancerCompletedNCT03414684Phase 2Results posted
• A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced SarcomaActive, not recruitingNCT03414229Phase 2Results posted
• A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)CompletedNCT03412773Phase 3Results posted
• Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerCompletedNCT03409614Phase 3Results posted
• Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)TerminatedNCT03407170Phase 2Results posted
• Regorafenib and Nivolumab Simultaneous Combination TherapyCompletedNCT03406871Phase 1Results posted
• Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)TerminatedNCT03406715Phase 2Results posted
• Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)Active, not recruitingNCT03405792Phase 2Results posted
• Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by SurgeryCompletedNCT03405155Phase 2Results posted
• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results posted
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results posted
• Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant MesotheliomaCompletedNCT03399552Phase 1/2Results posted
• Study of Pembrolizumab Following TACE in Primary Liver CarcinomaCompletedNCT03397654Phase 1/2Results posted
• Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaCompletedNCT03396952Phase 2Results posted
• Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal CancerCompletedNCT03396926Phase 2Results posted
• Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown PrimaryTerminatedNCT03396471Phase 2Results posted
• Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian CancerCompletedNCT03394885Phase 1/2Results posted
• Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)CompletedNCT03391973Phase 2Results posted

← Immune Checkpoint Inhibitors overview